What is Octave Bioscience?
Octave Bioscience, Inc. is at the forefront of developing advanced diagnostic solutions, specializing in the creation of innovative tests for neurodegenerative diseases. Their flagship product, the MSDA Test, is a pioneering multi-analyte blood test designed to meticulously monitor multiple sclerosis (MS) disease activity. This diagnostic tool provides highly personalized and detailed reporting, empowering both patients and healthcare providers with critical insights to make informed decisions regarding patient care. By enhancing clinical understanding of neurodegenerative conditions, Octave Bioscience aims to fundamentally transform the management and treatment landscape for individuals affected by MS. Their services are accessible nationwide through a partnership with Quest Diagnostics, targeting a broad audience of healthcare professionals and MS patients.
How much funding has Octave Bioscience raised?
Octave Bioscience has raised a total of $129M across 5 funding rounds:
Angel/Seed
$2.5M
Series A
$14M
Series B
$62M
Debt
$15.5M
Series C
$35M
Angel/Seed (2017): $2.5M, investors not publicly disclosed
Series A (2018): $14M led by BlueCross BlueShield Venture Partners, Echo Health Ventures, and Section 32
Series B (2023): $62M supported by Deerfield Communications Inc, Casdin Capital , LLC, Echo Health Ventures LLC, The Blue Venture Fund, Northpond Ventures LLC, and Section 32
Debt (2025): $15.5M featuring Silicon Valley Bank
Series C (2025): $35M backed by Hikma Ventures, Merck Global Health Innovation Fund, Novartis, Northpond Ventures, Byers Capital, Intermountain West Joint Venture, S32, The Blue Venture Fund, Valhalla Foundation, and Casdin Capital
Key Investors in Octave Bioscience
Section 32
Section 32 is a venture capital firm that focuses on investing in cutting-edge technology. Founded by Bill Maris, the firm is backed by a team with extensive experience in building iconic companies. Their investment strategy targets innovative startups and emerging technologies. S32 aims to support visionary entrepreneurs at the forefront of technological advancement.
BlueCross BlueShield Venture Partners
BlueCross BlueShield Venture Partners manages over $500 million in capital across three funds. The Funds work collaboratively with 29 different BCBS entities to invest in promising, emerging companies of strategic relevance to Blue Cross and Blue Shield Plans. The Blue Cross Blue Shield Association (BCBSA) serves as the focal point for the funds, providing governance and administration.
Novartis
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions. The company focuses on research and development of treatments across multiple therapeutic areas to address various medical conditions and improve patient outcomes worldwide.
What's next for Octave Bioscience?
The substantial capital infusion, particularly the recent major strategic investment, positions Octave Bioscience for accelerated growth and market expansion. This financing is expected to fuel further research and development, enhance the commercialization of the MSDA Test, and potentially broaden the company's diagnostic capabilities to other neurodegenerative conditions. The company's strategic partnerships, including its nationwide distribution through Quest Diagnostics, coupled with backing from prominent venture capital firms, suggest a clear trajectory towards becoming a leader in personalized diagnostics for neurological disorders. Future endeavors will likely focus on scaling operations, refining diagnostic accuracy, and solidifying its market presence in the competitive healthcare technology sector.
See full Octave Bioscience company page
